Home > News > BioSante Presents CaP-adjuvanted Bird Flu Vaccine Data
May 23rd, 2006
BioSante Presents CaP-adjuvanted Bird Flu Vaccine Data
Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced that Dr. Steve Bell, vice president of research and pre-clinical development, presented a case study highlighting the potential of BioVant(TM), the Company's calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, in influenza virus vaccines, including H5N1 avian influenza, or bird flu.
Source:
businesswire
Bookmark:
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Sensors innovations for smart lithium-based batteries: advancements, opportunities, and potential challenges August 8th, 2025
Deciphering local microstrain-induced optimization of asymmetric Fe single atomic sites for efficient oxygen reduction August 8th, 2025
Japan launches fully domestically produced quantum computer: Expo visitors to experience quantum computing firsthand August 8th, 2025
ICFO researchers overcome long-standing bottleneck in single photon detection with twisted 2D materials August 8th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||